RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh maintains an Outperform rating on Edwards Lifesciences (NYSE:EW) and raises the price target from $82 to $95, indicating a positive outlook on the company's stock.
February 07, 2024 | 5:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Shagun Singh maintains an Outperform rating on Edwards Lifesciences and raises the price target from $82 to $95.
The increase in price target by RBC Capital, along with the maintenance of an Outperform rating, suggests a strong positive outlook on Edwards Lifesciences. This is likely to instill confidence in investors and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100